2-(3,4-Dimethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane>98.0%(GC)(T)5g

(S)-Methyl 2-(morpholin-3-yl)acetate hydrochloride, 95.0%, 250mg

Ethyl 1-(azetidin-3-yl)-1H-1,2,3-triazole-4-carboxylate hydrochloride, 10g

2,3,5-Trimethylpyrazine>98.0%(GC)(T)25g

1,2,3,4-Tetrahydro-1,5-naphthyridine, 95.0%, 25g

[1-(3-aminopropyl)piperidin-2-yl]methanol, 95.0%, 1g

1,6-DIMETHYL-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBALDEHYDE, 95%, 50mg

Plan phase PLPHi S100x/1.25 oil immersion infinity corrected IOS objective. Working distance 0.36 mm

N-(4-Bromopyridin-2-yl)acetamide, 95.0%, 250mg

5-Bromo-2-fluoro-N-methoxy-N-methylbenzamide, 95+%, 5g

(S)-5-isopropyl-2-(perfluorophenyl)-2,5,6,8-tetrahydro-[1,2,4]triazolo[3,4-c][1,4]oxazin-4-iumtetrafluoroborate, 97%, 10g

(R)-2-(2-(Diphenylphosphino)phenyl)-4-isopropyl-4,5-dihydrooxazole, 95.0%, 100mg

2-(2-aminopropyl)phenol, 95.0%, 250mg